GLPwatch
Papers (12034)
Page 99 of 201, ranked by citation count.
- The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
- Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
- Genetic predictors of GLP1 receptor agonist weight loss and side effects.
- Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
- Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice.
- The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome.
- Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
- Glucagon-like peptide-1 receptors agonists (GLP1 RA).
- Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.
- Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents.
- Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion.
- Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice.
- Cardiovascular Effects of Liraglutide.
- Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.
- The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
- Exenatide and feeding: possible peripheral neuronal pathways.
- Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy.
- Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
- Acute Pancreatitis Likely Due to Semaglutide.
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.
- GHSR-1 agonist sensitizes rat colonic intrinsic and extrinsic neurons to exendin-4: A role in the manifestation of postprandial gastrointestinal symptoms in irritable bowel syndrome?
- Exendin-4 protects the hearts of rats from ischaemia/reperfusion injury by boosting antioxidant levels and inhibition of JNK/p<sup>66</sup> Shc/NADPH axis.
- Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.
- Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.
- Exendin-4 Improves Cognitive Function of Diabetic Mice via Increasing Brain Insulin Synthesis.
- Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
- Effects of Metformin on Renal Function, Cardiac Function, and Inflammatory Response in Diabetic Nephropathy and Its Protective Mechanism.
- [Exendin-4 alleviates diabetic cardiomyopathy in mice by regulating Sirt1/PGC1α].
- Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.
- The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity.
- Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective.
- Exendin-4 inhibits small intestinal glucose sensing and absorption through repression of T1R2/T1R3 sweet taste receptor signalling in streptozotocin diabetic mice.
- Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
- Extending our understanding of exenatide: a rare case of angio-oedema.
- Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.
- GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide).
- Weight Loss Therapies and Hypertension Benefits.
- Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes.
- Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
- Tirzepatide-associated starvation ketoacidosis.
- Skeletal Muscle Mass and Body Weight Fall Proportionally With Use of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Tirzepatide: Case Report and Review of Literature.
- Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit With GLP-1/Glucagon Agonism.
- Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study.
- Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?
- Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study.
- Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark.
- Liraglutide treatment counteracts alterations in adipose tissue metabolism induced by orchiectomy in rats.
- Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells.
- Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
- [Exendin-4 alleviates oxidative stress and liver fibrosis by activating Nrf2/HO-1 in streptozotocin-induced diabetic mice].
- Semaglutide and heart failure: Updated meta-analysis.
- [The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus].
- Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
- Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.
- Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease.
- Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.
- Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
- Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
- Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study.
- Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.